

**DSAD****ADAD**

# Genetically Determined Alzheimer's Disease: ADAD-DSAD Conference

## 3<sup>rd</sup> edition

Barcelona, April 9<sup>th</sup> and 10<sup>th</sup>, 2026

Modernist Hospital of Sant Pau (Pau Gil Room) and Online

### Presentation

This is the third edition of this groundbreaking conference, which aims to foster collaboration and knowledge exchange between the fields of Down Syndrome associated Alzheimer disease (DSAD) and autosomal dominant AD (ADAD). The event will feature research findings, clinical trials, and more, with an inclusive approach to diversity, representation, and accessibility.

Sessions are listed in Central European Standard Time (CEST). Schedule is current at the time of posting. Communications from across the world.

### Steering Committee

#### Chairs

**Juan Fortea.** Hospital of Sant Pau; Hub Alzheimer Barcelona. Barcelona, Spain

**Raquel Sánchez-Valle.** Hospital Clínic de Barcelona; Hub Alzheimer Barcelona. Barcelona, Spain

#### Members

**Natalia Acosta Baena.** Grupo de Neurociencias de Antioquia; Medellín, Colombia

**Beau Ances.** Washington University in St. Louis; Saint Louis, USA

**Sigan Hartley.** University of Wisconsin-Madison; Madison, USA

**Jason Hassenstab.** Washington University in St. Louis; St. Louis, USA

**Johannes Levin.** Ludwig-Maximilians-University of Munich and German Center for Neurodegenerative Diseases; Munich, Germany

**Michael Rafii.** USC Keck School of Medicine; San Diego, USA

**Laurie Ryan.** Division of Neuroscience, National Institute on Aging; Rockville, USA

**Natalie Ryan.** Dementia Research Centre, UCL Queen Square Institute of Neurology; London, UK

**Heather Snyder.** Alzheimer's Association; Chicago, USA

**Erika Tarver.** Division of Neuroscience, National Institute on Aging; Rockville, USA

### Scientific Committee

**María Carmona.** Hospital of Sant Pau; Barcelona, Spain

**Lisi Flores.** University of California; Irvine, USA

**Matthew Janicki.** University of Illinois Chicago; Rockport, USA

**Katherine Koenig.** The Cleveland Clinic; Cleveland, USA

**Patrick Lao.** Columbia University; New York, USA

**Sarah Walter.** University of Southern California; San Diego, USA

**Sára Erzsebet Zsadanyi.** Hospital of Sant Pau; Barcelona, Spain

7:30 am Registration

8:00 am Welcome & Opening Remarks

- [Raquel Sánchez-Valle](#). Hospital Clínic de Barcelona. IDIPABS; Barcelona, Spain
- [Juan Fortea](#). Hospital of Sant Pau; Barcelona, Spain
- [Arcadi Navarro](#). Fundació Pasqual Maragall, Hub Alzheimer Barcelona, Spain
- [Alberto Lleó](#). Hospital of Sant Pau; Barcelona, Spain
- [Sid O'Bryant](#). UNT Health Fort Worth (ITR); Texas, USA
- [María Carrillo](#). Alzheimer's Association; Chigaco, USA

8:30 am **Oral Session 1. Basic Science**

Moderators: Heather Snyder and Alberto Lleó

1. Characterization of Copathologies In APOE $\epsilon$ 4 Homozygotes  
[Iñigo Rodríguez-Baz](#). Hospital of Sant Pau; Barcelona, Spain
2. Neuropathologic Correlates of Cognitive Resilience to Alzheimer'S Disease In Down Syndrome  
[Lisi Flores-Aguilar](#). University of California; Irvine, USA
3. Potential Convergent Inflammatory and Vascular Drivers Of Tau Pathology And Clinical Progression In Adults With Down Syndrome  
[Natalie Edwards](#). Columbia University; New York, USA
4. Socioeconomic Status And Disease Progression In Dominantly Inherited Alzheimer'S Disease  
[María Florencia Clarens](#). Fleni; Argentina

10:00 am Coffee Break & Networking

10:30 am **Symposium 1. Lessons Learned from Clinical Trials in ADAD & DSAD**

Moderators: Michael Rafii and Natalie Ryan

- ALADDIN: Amyloid Lowering for Alzheimer's in Down's with Donanemab Investigation  
[Zinayida Schlachetzki](#). USC Epstein Family Alzheimer's Therapeutic Research Institute; California, USA
- Post-mortem drug binding studies that he has done with sAD and DSAD  
[Jasmeer Chhatwal](#). Harvard Medical School; Massachusetts, USA
- Alzheimer's Prevention Initiative-Colombia (API-Colombia)  
[David Aguillón](#). Grupo de Neurociencias de Antioquia; Antioquia, Colombia

12:00 am **Oral Session 2. Clinical and Neuropsychological**

Moderators: Jason Hassenstab and Sigán Hartley

1. Designing A Reserve And Lifestyle Assessment For People With Down Syndrome (RLS-DS): An ISTAART-Led Initiative  
[Lidia Vaqué-Alcázar](#). Hospital of Sant Pau; Barcelona, Spain
2. Trajectories Of Cognitive Functioning In Adults With Down Syndrome Based On Residence  
[Dasoo Milton Yoon](#). University of Wisconsin-Madison; Wisconsin, USA

3. Epilepsy In Adults With Down Syndrome: A Multicentre Clinical Study

**Lucia Maure-Blesa.** Hospital of Sant Pau; Barcelona, Spain

4. Survival After Alzheimer's Dementia Diagnosis In Down Syndrome: The Role Of Genetics, Care And Clinical Factors

**Eimear McGlinchey.** Trinity College Dublin; Dublin, Ireland

1:30 pm

Lunch and Poster Session 1 (*even-numbered posters*)

Moderators: María Carmona and Neus Falgàs

3:00 pm

**Keynote: Colombia ADAD cohort**

Moderator: Raquel Sánchez-Valle

- **David Aguillón.** Grupo de Neurociencias de Antioquia; Antioquia, Colombia

4:30 pm

**The Lancet perspective**

- **Beatriz Gómez Pérez-Nievas.** The Lancet; London, UK
- **Morgane Boillot.** The Lancet Neurology; Valencia, Spain

5:00 pm

End of Day 1

**Friday, April 10<sup>th</sup>, 2026**

**Pau Gil Room**

8:00 am

Registration

8:30 am

**Oral Session 3. Fluid Biomarkers**

Moderators: Daniel Alcolea and Mircea Balasa

1. The Interactive Role Of Apoe And Sex In Down Syndrome Alzheimer's Disease  
**Julie Wisch.** Washington University Medical School; St. Louis, USA
2. Nulisa Blood Based CNS Biomarker Panel Across The Adult Lifespan Of Down Syndrome  
**Beau Ances.** Washington University in Saint Louis; St. Louis, USA
3. Cerebrospinal Fluid Proteomic Profiling And Biomarker Discovery In Autosomal Dominant Alzheimer's Disease  
**Laura Ibáñez.** Washington University School of Medicine; St. Louis, USA
4. Proteomic Profiling Of Cerebrospinal Fluid And Plasma In Autosomal-dominant Alzheimer's Disease  
**Aina Comas-Albertí.** Hospital Clínic de Barcelona; Barcelona, Spain

10:00 am

**Symposium 2. Making Research Participation Meaningful: Perspectives of Adults with ADAD and Their Family Members**

Moderators: Sarah Walter and Beatriz Bosch

11:00 am Coffee Break & Networking

11:30 am **Oral Session 4. Neuroimaging and Emerging Biomarkers**

Moderators: Beau Ances and Alexandre Bejanin

1. Distinct Temporal Patterns Of Tau Pet And Plasma Biomarkers In Autosomal Dominant Alzheimer's Disease  
**Mariola Zapater Fajarí**. Karolinska Institutet; Solna, Sweden
2. Concordance Of Biological And Clinical Staging In Down Syndrome Associated Alzheimer's Disease  
**Jason Russell**. Epstein Family Alzheimer's Therapeutic Research Institute; California, USA
3. Plasma Phospho-tau217 Correlates With Amyloid And Tau PET Measures In People With Down Syndrome  
**Zinayida Schlachetzki**. USC Epstein Family Alzheimer's Therapeutic Research Institute; California, USA
4. Resting-state fMRI in individuals with Down Syndrome, with or without Alzheimer's Disease: a Systematic Review  
**Leda Bianchi**. King's College London; London, UK

1:00 pm Lunch and Poster Session 2 (*odd-numbered posters*)  
Moderators: Núria Guillén and Isabel Barroeta

2:00 pm **Symposium 3. Perspectives from Latin America. Focus: Research capacity, care models, and trial readiness**

Moderators: Sid O'Bryant and Natalia Vilor

- Down syndrome and Alzheimer's disease  
**Agustín Ibáñez**. Global Brain Health Institute, Trinity College Dublin; Dublin, Ireland
- Genetic Alzheimer's disease work from ReDLat  
**Carolina Ochoa**. BrainLat Institute UAI, Universidad Adolfo Ibáñez; Santiago, Chile
- LATAM FINGERS  
**Lucia Crivelli**. Fleni; Argentina
- Social epigenetics  
**Hernando Santamaría-García**. Universidad Javeriana; Bogotá, Colombia

3:30 pm **Symposium 4. Making Research Participation Meaningful: Perspectives of Adults with DSAD and Their Family Members**

Moderators: Isabel Barroeta and Eimear McGlinchey

4:00 pm **Life Achievement Award**

Presenters: Juan Fortea and Raquel Sánchez-Valle

- DSAD: Down syndrome and Alzheimer disease: a neurological perspective  
**Ira Lott**. University of California; Irvine, USA
- ADAD: Faltering steps towards mechanistic therapies in neurodegenerative diseases  
**John Hardy**. University College London; London, UK

5:30 pm Closing Remarks  
**Maria Carrillo, Raquel Sánchez-Valle and Juan Fortea**

**Posterboard 1. Basic Science and Pathogenesis**

Room 1902 (floor -1)

- P01 Establishing A Spanish Cohort Of Adults With Down Syndrome  
**Marta Rovira-Bruna**. ACE Alzheimer Barcelona; Barcelona, Spain
- P02 Compensatory Locus Coeruleus Hyperactivity Drives Behavioral Symptoms In Prodromal Alzheimer's Disease **No presented**  
**David Weinshenker**. Emory University School of Medicine; Atlanta, USA
- P03 Oligomeric Tau Correlates With Seeding Activity In Different Forms Of Alzheimer's Disease  
**Érika Sánchez-Aced**. Institut de Recerca Sant Pau; Barcelona, Spain
- P04 Mapping Peripheral Immune Alterations Along The Alzheimer'S Disease Continuum In Down Syndrome At Single-cell Resolution  
**Oriol Dols-Icardo**. Institut de Recerca Sant Pau; Barcelona, Spain
- P05 Impact Of Genetic Ancestry On Age-related Expression Changes And Adrd Risk  
**Manuel Hurtado Jr.** Northwestern University; Illinois, USA
- P06 Independent Generation Of Amyloid-beta Via Novel App Transcript Variants **No presented**  
**Charlie Arber**. UCL Institute of Neurology; London, UK
- P07 Aims And Ambitions Of The New BHF-UKDRI Centre For Vascular Dementia Research  
**Catherine Hall**. University College London; London, UK
- P08 Cellular And Spatial Determinants Of Selective Neuronal Vulnerability In The Alzheimer's Disease Entorhinal Cortex  
**Sam Boulger**. Imperial College London; London, UK

**Posterboard 2. Biomarkers and Neuroimaging 1**

Room 1902 (floor -1)

- P09 Plasma P-tau217 As A Biomarker Of Down Syndrome-related Alzheimer's Disease (dsad)  
**Lucía Pertierra**. Fleni; Argentina
- P10 Sex-specific Volumetric And Morphological Hippocampal Atrophy Associated With Alzheimer'S Disease In Down Syndrome  
**Luis Echeverry Quiceno**. University of Barcelona; Barcelona, Spain
- P11 Apoe Genotype-dependent Neurodegenerative Patterns In Alzheimer's Disease Revealed By Explainable Machine Learning  
**Sofía Gassó**. Universitat Oberta de Catalunya; Barcelona, Spain
- P12 Changes In Cortical Asymmetry In Down Syndrome Across Stages Of Alzheimer's Disease  
**Agnès Pérez-Millan**. Hospital Clínic de Barcelona. Fundació Recerca Clínic Barcelona-IDIBAPS; Barcelona, Spain
- P13 The Antagonistic Pleiotropy Of Tau Phosphorylation: CSF And Plasma Tau Species In Newborns And Alzheimers Disease **No presented**  
**Fernando Gonzalez-Ortiz**. Gothenburg University; Gothenburg, Sweden
- P14 Validation Of The Face-Name Associative Memory Exam For Adults With Down Syndrome  
**Natàlia Casart**. IR Sant Pau, Hospital de la Santa Creu i Sant Pau; Barcelona, Spain

- P15 Alterations In Circadian Rest-Activity Rhythms Along The Alzheimer's Disease Spectrum In Down Syndrome  
**Lidia Vaqué-Alcázar**. Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Barcelona, Spain
- P16 Spectral Sleep Eeg Biomarkers Of Cognitive Decline In Adults With Down Syndrome  
**Sandra Gimenez**. IR SANT PAU, Hospital de la Santa Creu i Sant Pau; Barcelona, Spain
- P17 Improving Feasibility Of Cerebral Amyloid Angiopathy Assessment In People With Down Syndrome Using Accelerated Mri Protocols  
**Mona Beidas**. King's College London; London, UK

**Posterboard 3. Biomarkers and Neuroimaging 2**

Room 1 (floor -1)

- P18 Phosphorylated Tau 217 in Adolescents and Young Adults with Down Syndrome and Down Syndrome Regression Disorder  
**Giulia Livrizzi**. Epstein Family Alzheimer's Therapeutic Research Institute; California, USA
- P19 Utility Of Combined Inflammatory Biomarker Panel Compared To Single Neuroinflammatory Biomarker Gfap In The Detection Of DS-AD  
**Melissa Petersen**. University of North Texas Health Science Center; Texas, USA
- P20 Regional Amyloid-PET Dynamics In Patients Treated With Anti-A $\beta$  Monoclonal Antibody Therapy  
**Alma Ghirelli**. San Raffaele Scientific Institute; Milan, Italy
- P21 Regional Cingulum White Matter Vulnerability In Down Syndrome: Cross-sectional And Longitudinal Diffusion Mr Tractography  
**Phoebe Ivain**. King's College London; London, UK
- P22 MRI-Free Quantification Of Amyloid Pet In Down Syndrome: Influence Of Reference/Target Region And Normalization Template  
**Maria Franquesa-Mullerat**. IR Sant Pau, Hospital de la Santa Creu i Sant Pau; Barcelona, Spain
- P23 Clinically Oriented Latent Representations Of 3d Brain Mri For Detection Of Alzheimer's Disease In Adults With Down Syndrome  
**Jordi Malé**. La Salle - Universitat Ramon Llull; Barcelona, Spain
- P24 High-frequency Oscillations Associate With Cognitive Performance In Down Syndrome-associated Alzheimer's Disease Dementia  
**Christos Lisgaras**. NYU Langone Health; New York, USA
- P25 The Association Between Choroidal Thickness And Ab42/40 Ratio In People With Down Syndrome And Older Healthy Adults  
**Julie-Anne Little**. Ulster University; Belfast, UK
- P26 SPARE-Tau, A Tau-pet Index, Outperforms Imaging And Fluid Biomarkers For Predicting Alzheimer's Disease Progression  
**David Wang**. University of Texas San Antonio Health Science Center; Texas, USA
- P27 Sleep Micro-architecture Predicts Magnetic-resonance Imaging Markers Of Brain Aging In A Longitudinal Cohort  
**Hanyi Jiang**. University of Greifswald; Greifswald, Germany

**Posterboard 4. Public Health and Community Research and Clinical Manifestations and Care**

Room 2 (floor -1)

- P28 Understanding Expertise: A Comparison Of Inclusive Research Approaches To Engage The Down Syndrome Community  
**Ashley Scott.** Boston University School Of Public Health; Boston, USA
- P29 Effective Community Partnership In DSAD Research **No presented**  
**Ann Cohen.** University of Pittsburgh; Pensilvania, USA
- P30 Digital Transition In Down Syndrome Cognitive Screening: A Validation Of Remote Camcog-ds And Mcrt Administration  
**Concepción Padilla.** Universitat Oberta de Catalunya; Barcelona, Spain
- P31 Epidemiology Of DSAD In The US 2011-2022: Impact Of The Covid-19 Pandemic And DSAD Related Deaths  
**Eric Rubenstein.** Boston University; Boston, USA
- P32 Improving Dementia Diagnosis In Down Syndrome Qualitative Research With People With Down Syndrome And Families  
**Madeleine Healy.** Monash University, Monash Health; Australia
- P33 Alzheimer's Disease Drug Repurposing Pipeline: 2026  
**Jeffrey Cummings.** University of Nevada, Las Vegas (UNLV); Nevada, USA
- P34 Cognitive And Behavioural Trajectories Across The Lifespan In Down Syndrome: A Cross-sectional Study  
**Katja Sandkühler.** LMU University Hospital; München, Germany
- P35 Using Machine Learning To Identify Predictors Of Death Among Medicaid And Medicare Enrolled Adults With Down Syndrome  
**Salina Tewolde.** Boston University; Boston, USA
- P36 Characterization Of Eating Disorders In Adad E280a Psen1 Mutation Carriers  
**Olga Patricia Dorado Gaviria.** Grupo de Neurociencias de Antioquia (GNA); Antioquia, Colombia
- P37 A Case Report Of Lewy Body Dementia In A Patient With Down Syndrome  
**Anne-Sophie Rebillat.** Institut Jerome Lejeune; France
- P38 Profiles Of Adaptive Behavior And Association With Alzheimer's Disease Pathology Longitudinally In Adults With Down Syndrome  
**Jennifer Bruno.** Stanford University; California, USA
- P39 Unraveling Genetic Susceptibility To Cognitive Impairment Through Whole-genome Sequencing Of 10,306 Chinese Individuals  
**Feifan Zhao.** Shanghai 9th People's Hospital; Shanghai, China
- P40 Importance Of Language-specific Diagnostic Markers In Understudied Languages In AD And PPA  
**Arpita Bose.** University of Reading; Berkshire, UK

## ORGANISERS



# FCSD...

Fundació Catalana Síndrome de Down

## WITH THE SUPPORT OF



**INSTITUTE FOR  
TRANSLATIONAL RESEARCH**  
Health and Aging Brain Study-Health Disparities



## SPONSORS

Silver



## TECHNICAL SECRETARIAT

Suport Serveis - secretaria@suportserveis.com - T. +34 93 201 75 71 - www.dsad-adad.com